Teva (TEVA) net profit rises to $380M from $320M.
The 4.8% increase in revenue was primarily attributable to higher sales of generic medicines in the U.S., specialty medicines globally and OTC products. The rise was partially offset by a decrease in generics sales outside the U.S., mostly in Japan due to the weaker yen, and API sales to third parties.
Revenue breakdown: total generics +1% to $2.7B; specialty medicines +5% to $2.2B. Copaxone +8% to $1.1B.
Teve reaffirms its 2014 outlook.
Declares 2013 dividend of 1.21 shekels ($0.34) a share, +5% from Q3. The record date will be February 24, and the payment date March 10. Tax will be withheld at a rate of 15%. (PR)